Skip to main content

Compare Stocks

Date Range: 

 Spectrum PharmaceuticalsViking TherapeuticsForte BiosciencesMolecular TemplatesGeron
SymbolNASDAQ:SPPINASDAQ:VKTXNASDAQ:FBRXNASDAQ:MTEMNASDAQ:GERN
Price Information
Current Price$3.48$6.17$31.61$7.86$1.43
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score1.51.61.72.01.4
Analysis Score3.43.63.53.43.5
Community Score2.83.53.52.62.7
Dividend Score0.00.00.00.00.0
Ownership Score0.80.80.83.30.8
Earnings & Valuation Score0.60.00.60.60.0
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$9.75$16.89$80.50$14.50$4.20
% Upside from Price Target180.17% upside173.73% upside154.67% upside84.48% upside193.71% upside
Trade Information
Market Cap$541.88 million$481.88 million$427.11 million$440.85 million$455.55 million
Beta2.512.020.232.081.5
Average Volume2,604,2341,259,706173,876433,3533,279,361
Sales & Book Value
Annual Revenue$109.33 millionN/A$40,000.00$22.27 million$460,000.00
Price / Sales4.96N/A10,677.8619.80990.33
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$1.69 per share$3.83 per share$6.81 per share$2.79 per share$0.68 per share
Price / Book2.06N/A4.642.822.10
Profitability
Net Income$-112,690,000.00$-25,780,000.00$-63,520,000.00$-69,420,000.00$-68,550,000.00
EPS($1.14)($0.36)($40.33)($1.26)($0.36)
Trailing P/E RatioN/AN/AN/AN/AN/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/AN/A-428.65%-21,631.02%
Return on Equity (ROE)-98.90%-13.57%-417.87%-111.43%-43.76%
Return on Assets (ROA)-69.77%-13.14%-248.28%-56.35%-37.24%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.05%N/AN/A0.18%0.10%
Current Ratio3.48%27.08%8.97%3.21%9.60%
Quick Ratio3.48%27.09%8.97%3.21%9.60%
Ownership Information
Institutional Ownership Percentage63.56%54.13%53.03%60.73%55.51%
Insider Ownership Percentage5.04%3.70%10.90%38.20%7.70%
Miscellaneous
Employees17518923653
Shares Outstanding155.71 million78.10 million13.51 million56.09 million318.57 million
Next Earnings Date8/9/2021 (Estimated)8/4/2021 (Estimated)8/9/2021 (Estimated)8/5/2021 (Estimated)8/5/2021 (Estimated)
OptionableOptionableOptionableNot OptionableNot OptionableOptionable
SourceHeadline
Geron Co. Expected to Earn Q2 2021 Earnings of ($0.09) Per Share (NASDAQ:GERN)Geron Co. Expected to Earn Q2 2021 Earnings of ($0.09) Per Share (NASDAQ:GERN)
americanbankingnews.com - May 14 at 8:56 AM
Geron Co. (NASDAQ:GERN) Expected to Announce Quarterly Sales of $80,000.00Geron Co. (NASDAQ:GERN) Expected to Announce Quarterly Sales of $80,000.00
americanbankingnews.com - May 14 at 1:22 AM
Geron Announces Two Presentations at Upcoming European Hematology Association Annual Congress - Business WireGeron Announces Two Presentations at Upcoming European Hematology Association Annual Congress - Business Wire
businesswire.com - May 13 at 3:33 AM
Geron Co. (NASDAQ:GERN) Expected to Post Earnings of -$0.08 Per ShareGeron Co. (NASDAQ:GERN) Expected to Post Earnings of -$0.08 Per Share
americanbankingnews.com - May 12 at 7:18 PM
Geron Announces Two Presentations at Upcoming European Hematology Association Annual Congress - Yahoo FinanceGeron Announces Two Presentations at Upcoming European Hematology Association Annual Congress - Yahoo Finance
finance.yahoo.com - May 12 at 5:17 PM
Geron Announces Two Presentations at Upcoming European Hematology Association Annual Congress - Galveston County Daily NewsGeron Announces Two Presentations at Upcoming European Hematology Association Annual Congress - Galveston County Daily News
galvnews.com - May 12 at 12:15 PM
Geron Announces Two Presentations at Upcoming European Hematology Association Annual CongressGeron Announces Two Presentations at Upcoming European Hematology Association Annual Congress
finance.yahoo.com - May 12 at 12:15 PM
Trial to Investigate Experimental Drugs Effect on Improving Survival in Refractory Myelofibrosis - Curetoday.comTrial to Investigate Experimental Drug's Effect on Improving Survival in Refractory Myelofibrosis - Curetoday.com
curetoday.com - May 11 at 5:55 PM
Geron: Q1 Earnings Snapshot - Greenwich TimeGeron: Q1 Earnings Snapshot - Greenwich Time
greenwichtime.com - May 11 at 5:55 PM
Is it Time to Dump Geron Corporation (GERN) Stock After it Has Fallen 2.92% in a Week? - InvestorsObserverIs it Time to Dump Geron Corporation (GERN) Stock After it Has Fallen 2.92% in a Week? - InvestorsObserver
investorsobserver.com - May 11 at 5:55 PM
Analysts’ Top Healthcare Picks: Avadel Pharmaceuticals (AVDL), Geron (GERN) - Smarter AnalystAnalysts’ Top Healthcare Picks: Avadel Pharmaceuticals (AVDL), Geron (GERN) - Smarter Analyst
smarteranalyst.com - May 11 at 12:54 PM
Geron (GERN) Received its Third Buy in a Row - Smarter AnalystGeron (GERN) Received its Third Buy in a Row - Smarter Analyst
smarteranalyst.com - May 11 at 12:54 PM
Geron: Q1 Earnings Snapshot - Centre Daily TimesGeron: Q1 Earnings Snapshot - Centre Daily Times
centredaily.com - May 11 at 12:54 PM
Geron (GERN) Q1 2021 Earnings Call Transcript - Motley FoolGeron (GERN) Q1 2021 Earnings Call Transcript - Motley Fool
fool.com - May 11 at 12:54 PM
Geron (NASDAQ:GERN) Announces  Earnings Results, Misses Expectations By $0.01 EPSGeron (NASDAQ:GERN) Announces Earnings Results, Misses Expectations By $0.01 EPS
americanbankingnews.com - May 11 at 12:34 PM
Geron: Q1 Earnings Snapshot - San Francisco ChronicleGeron: Q1 Earnings Snapshot - San Francisco Chronicle
sfchronicle.com - May 11 at 7:54 AM
Geron (GERN) Reports Q1 Loss, Tops Revenue Estimates - Yahoo FinanceGeron (GERN) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
finance.yahoo.com - May 11 at 7:54 AM
Geron (GERN) Q1 2021 Earnings Call TranscriptGeron (GERN) Q1 2021 Earnings Call Transcript
finance.yahoo.com - May 11 at 7:54 AM
Washington Lineman Cornelius Lucas Fires Back At Media Clowns - Sports IllustratedWashington Lineman Cornelius Lucas Fires Back At Media 'Clowns' - Sports Illustrated
si.com - May 11 at 12:16 AM
Geron: Q1 Earnings Snapshot - Modesto BeeGeron: Q1 Earnings Snapshot - Modesto Bee
modbee.com - May 11 at 12:16 AM
Geron (GERN) Reports Q1 Loss, Tops Revenue Estimates - NasdaqGeron (GERN) Reports Q1 Loss, Tops Revenue Estimates - Nasdaq
nasdaq.com - May 10 at 7:15 PM
Geron: Q1 Earnings Insights - BenzingaGeron: Q1 Earnings Insights - Benzinga
benzinga.com - May 10 at 7:15 PM
Geron: Q1 Earnings Snapshot - Sacramento BeeGeron: Q1 Earnings Snapshot - Sacramento Bee
sacbee.com - May 10 at 7:15 PM
Geron Corporation Reports First Quarter 2021 Financial Results and Recent Highlights - Business WireGeron Corporation Reports First Quarter 2021 Financial Results and Recent Highlights - Business Wire
businesswire.com - May 10 at 7:15 PM
Geron (GERN) Reports Q1 Loss, Tops Revenue EstimatesGeron (GERN) Reports Q1 Loss, Tops Revenue Estimates
finance.yahoo.com - May 10 at 7:15 PM
DateCompanyBrokerageAction
4/12/2021Spectrum PharmaceuticalsB. RileyReiterated Rating
10/26/2020Spectrum PharmaceuticalsHC WainwrightLower Price Target
9/17/2020Spectrum PharmaceuticalsJMP SecuritiesInitiated Coverage
7/28/2020Spectrum PharmaceuticalsCantor FitzgeraldBoost Price Target
12/26/2019Spectrum PharmaceuticalsGuggenheimDowngrade
3/15/2019Spectrum PharmaceuticalsJefferies Financial GroupReiterated Rating
5/3/2021Viking TherapeuticsSVB LeerinkReiterated Rating
1/22/2021Viking TherapeuticsStifel NicolausReiterated Rating
10/29/2020Viking TherapeuticsRaymond JamesBoost Price Target
9/11/2020Viking TherapeuticsWilliam BlairReiterated Rating
9/1/2020Viking TherapeuticsBTIG ResearchBoost Price Target
8/31/2020Viking TherapeuticsChardan CapitalBoost Price Target
7/29/2020Viking TherapeuticsOppenheimerReiterated Rating
6/4/2020Viking TherapeuticsBMO Capital MarketsInitiated Coverage
5/2/2020Viking TherapeuticsMaxim GroupInitiated Coverage
4/1/2021Forte BiosciencesCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellInitiated Coverage
3/26/2021Forte Biosciences(FBRC)Initiated Coverage
8/28/2020Forte BiosciencesBrookline Capital ManagementInitiated Coverage
8/25/2020Forte BiosciencesTruist SecuritiInitiated Coverage
6/22/2020Forte BiosciencesLADENBURG THALM/SH SHInitiated Coverage
4/27/2021Molecular TemplatesBank of AmericaInitiated Coverage
2/1/2021Molecular TemplatesUBS GroupInitiated Coverage
2/27/2020Molecular TemplatesBarclaysInitiated Coverage
11/13/2019Molecular TemplatesCowenReiterated Rating
12/11/2018Molecular TemplatesCIBCInitiated Coverage
11/15/2018Molecular TemplatesEvercore ISIInitiated Coverage
10/8/2018Molecular TemplatesLaidlawInitiated Coverage
6/17/2020GeronNeedham & Company LLCReiterated Rating
9/27/2018GeronS&P Equity ResearchLower Price Target
(Data available from 5/16/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.